A Phase 2 interventional study of SPI-1005 200mg and SPI-1005 400mg in Noise Induced Hearing Loss, sponsored by Sound Pharmaceuticals, Incorporated. Withdrawn at 5 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Sound Pharmaceuticals, Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Hearing Loss, Noise-Induced with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Hearing Loss, Noise-Induced · United States.
Among the 24 studies in Hearing Loss, Noise-Induced with a site in United States, this one is the 21st largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 2, and was the 9th registered.
46 studies on the registry are indexed under Hearing Loss, Noise-Induced; 10 are open to participants now.
Browse Hearing Loss, Noise-Induced studies →6 of the 24 studies in Hearing Loss, Noise-Induced with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 45–65
Restorear Devices LLC · Sites in United States
Ages 18–55 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 2–6
San Diego State University · Sites in United States
Ages 18+ · Healthy volunteers
Truway Health, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Hearing Loss, Noise-Induced studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 1
First in 1999; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 106 across the 22 interventional studies, 134,119 across the 2 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 24 have an industry lead sponsor. The 10 most frequent:
Sound Pharmaceuticals, Incorporated is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Sound Pharmaceuticals, Incorporated has 1 study filed under Hearing Loss, Noise-Induced — fewer than ten, so there is no comparison to draw.
1 of the studies in Hearing Loss, Noise-Induced with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06729632Restorear Devices LLCNon-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Hearing Loss, Noise-Induced with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SPI-1005 is a novel oral drug that contains a glutathione peroxidase mimetic (ebselen) that will be tested in subjects with a history of NIHL at risk for additional NIHL. The goal of this multi-center Phase 2b study is to determine whether SPI-1005 is effective in reducing an acute NIHL in this affected population. In this Phase 2b study subjects with prior NIHL will be enrolled and exposed to a calibrated sound challenge (CSC) that induces a slight acute NIHL.
Randomized, double-blind, placebo-controlled, safety and efficacy study of oral SPI-1005 in adults with Noise Induced Hearing Loss (NIHL). All recruited subjects will have their severity of NIHL determined before the start of SPI-1005 treatment using various hearing tests. Subjects will be enrolled and randomized to either placebo or SPI-1005. Subjects will be dosed with either placebo or SPI-1005 for 7 days, beginning 1 day before an acute NIHL. Subjects will have hearing tests performed before and immediately after a calibrated sound challenge (CSC). Follow-up hearing tests will be performed post-CSC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 mg SPI-1005, capsule, bid, po, x7d
Drug: SPI-1005 200mg
400 mg SPI-1005, capsule, bid, po, x7d
Drug: SPI-1005 400mg
0 mg SPI-1005, capsule, bid, po, x7d
Drug: Placebo
Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
Also known as: Low Dose
Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
Also known as: High Dose
Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
Also known as: Control
Reduction in the Incidence of a Significant Threshold Shift
Post Controlled Sound Challenge pure tone audiometry will be compared with baseline
Time frame: Within 1 day
Improvement in word recognition score
Post Controlled Sound Challenge Words in Noise Test score will be compared with baseline
Time frame: Within 1 day
Adverse events
Adverse events due to study drug will be compared with placebo
Time frame: Within 7 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ebselen
Sound Pharmaceuticals, Incorporated